The role of molecular techniques in the clinical management of leukemia. Lessons from the Philadelphia chromosome
- PMID: 1516023
- DOI: 10.1002/1097-0142(19920915)70:4+<1695::aid-cncr2820701608>3.0.co;2-d
The role of molecular techniques in the clinical management of leukemia. Lessons from the Philadelphia chromosome
Abstract
The Philadelphia chromosome (Ph1) was the first genetic change to be associated consistently with leukemia, and it is one of the best understood on the molecular level. Because of this, it is an excellent model to investigate the application of molecular techniques to the clinical setting. These techniques are reviewed as are their clinical use in chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), and transplantation. The Ph1 is caused by the fusion of two genes on chromosomes 9 and 22, resulting in the BCR-ABL fusion gene. This new gene is believed to be the cause of these Ph1-positive leukemias. The ability to detect the BCR-ABL fusion gene evolved from cytogenetic detection to Southern blot analysis, and now includes sophisticated techniques such as polymerase chain reaction (PCR) methods and pulsed-field gels. Diagnosis of the BCR-ABL fusion gene by Southern blot detection of bcr genetic rearrangements is the prototype of molecular cancer diagnosis. The sensitivity and clinical uses of this test are reviewed, especially its application to monitoring the response to treatment. PCR methods enable the researcher to detect 1 CML cell in a population of 10(5) cells. Clinical experience with PCR, especially in transplantation medicine, is providing a better understanding of the meaning of the terms "remission" and "cure." Newer techniques using fluorescent in situ hybridization have considerable potential for BCR-ABL detection, but no clinical experience has been gained with these techniques currently. The diagnosis of the BCR-ABL fusion gene in ALL has important clinical implications because it is the most common molecular genetic change in adult ALL and is associated with short remissions and poor outcome in all age groups. Diagnosis of the BCR-ABL fusion in ALL is difficult because the molecular findings are more heterogeneous than they are in CML. The methods available and their accuracy and sensitivity are compared. A review of their clinical impact is included.
Similar articles
-
[Detection on BCR-ABL fusion gene in Ph1 chromosome positive leukemia by "nested" retrotranscriptase/polymerase chain reaction].Zhonghua Yi Xue Za Zhi. 1994 Nov;74(11):662-5, 708. Zhonghua Yi Xue Za Zhi. 1994. PMID: 7866899 Chinese.
-
Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia.Proc Natl Acad Sci U S A. 1989 Jun;86(11):4259-63. doi: 10.1073/pnas.86.11.4259. Proc Natl Acad Sci U S A. 1989. PMID: 2498881 Free PMC article.
-
Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.Leuk Res. 1999 Mar;23(3):207-15. doi: 10.1016/s0145-2126(98)00171-4. Leuk Res. 1999. PMID: 10071072 Review.
-
Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities.Leukemia. 2003 Jun;17(6):1124-9. doi: 10.1038/sj.leu.2402963. Leukemia. 2003. PMID: 12764379
-
Molecular methods to detect the Philadelphia chromosome.Clin Lab Med. 1990 Dec;10(4):839-55. Clin Lab Med. 1990. PMID: 2272177 Review.
Cited by
-
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.Int J Mol Sci. 2021 Oct 10;22(20):10931. doi: 10.3390/ijms222010931. Int J Mol Sci. 2021. PMID: 34681592 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Miscellaneous